Publication Topic

Keeton KA, Blanchette A, Benson SM, Covell LT, Madl AK. Analysis and comparison of nicotine pharmacokinetics of modern oral nicotine pouches. Poster Presentation 48 at the 77th Tobacco Science Research Conference, Atlanta, GA, September 2024.

Racz L, Mittal L, Perry CS, Blanchette A, Proctor D. Assessing sustainable applications of electric arc furnace steel slag as construction aggregate: Applications of probabilistic risk assessment and physiologically-based pharmacokinetic modeling. Poster presented at Society of Environmental Toxicology and Chemistry North America 44^th Annual Meeting, Louisville, KY, November 2023.

Perry CS, Blanchette AD, Vivanco SN, Verwiel AH, Proctor DM. 2023. Use of physiologically based pharmacokinetic modeling to support development of an acute (24-hour) health-based inhalation guideline for manganese. Regul Toxicol Pharmacol 145:105518; doi: 10.1016/j.yrtph.2023.105518. PMID: 3786341.

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145(Dec):105521; doi: 10.1016/j.yrtph.2023.105521. PMID: 37863416.

Grover A, Sankaranarayanan S, Mathur V, Suri P, Qiu H, Andrews-Zwilling Y, Mease K, Taylor LK, Cahir-McFarland E, Keswani S, Yednock T. 2023. Pharmacokinetic and target engagement measures of ANX007, an anti-C1q antibody fragment, following intravitreal administration in nonhuman primates. Invest Opthalmol Visual Sci 64(2)3; 10.1167/iovs.64.2.3. PMID: 36729444.

Ramírez-Valle F, Adams M, Beebe L, Chen J, Chuaqui C, Connarn JN, Corin AF, Dingley KH, et al. 2019. A novel MK2 inhibitor for the treatment of ankylosing spondylitis and other inflammatory diseases. Abstract 1536, Annual Meeting of the American College of Rheumatology Conference, Atlanta, GA, November 2019.

Casey WM, Chang X, Allen DG, Ceger PC, Choksi NY, Hsieh JH, et al. 2018. Evaluation and optimization of pharmacokinetic models for in vitro to in vivo extrapolation of estrogenic activity for environmental chemicals. Environ Health Perspect 126(9):97001; doi: 10.1289/EHP1655.

Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. J Appl Toxicol 38:351–365. doi: 10.1002/jat.3545.

Harper BH, Wang L, Zhu C, Kar NF, Li B, Moyes CR, … Dingley K, et al. 2017. Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder. Bioorg Med Chem Lett 27(4):1094–1098; doi: 10.1016/j.bmcl.2016.12.033. PMID: 28089699.

Zhu C, Wang L, Zhu Y, Guo ZZ, Liu P, Hu Z, … Dingley KH, et al. 2017. Discovery of phenyl acetamides as potent and selective GPR119 agonists. Bioorg Med Chem Lett 27(5):1124–1128; doi: 10.1016/j.bmcl.2017.01.091. PMID: 28185720.

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325(15 June):9-17; doi: 10.1016/j.taap.2017.03.023.

Borghoff SJ, Ring C, Banton MI, Leavens TL. Ethyl tertiary butyl ether (ETBE) and tertiary butyl alcohol (TBA) physiologically based pharmacokinetic (PBPK) model in rats: Contribution of binding to 2u-globulin and non-linear kinetics to kidney and liver responses in rats. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Kirman CR, Proctor D, Suh M, Haws L, Harris M, Thompson C, Hays S. Using physiologically based pharmacokinetic modeling to address potentially sensitive subpopulations exposed to hexavalent chromium. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

Campbell J, Franzen A, Van Landingham C, Lumpkin M, Crowell S, Meredith C, Loccisano A, Gentry R, Clewell H. 2016. Predicting lung dosimetry of inhaled particle-borne benzo(a)pyrene using physiologically based pharmacokinetic modeling. Inhal Toxicol 28(11):520–535; doi: 10.1080/08958378.2016.1214768.

Chang X, Kleinstreuer N, Ceger P, Choksi NY, Hseih J, DeVito M, Allen DG, Casey W. Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Poster presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Unice KM, Kerger BD, Paustenbach DJ, Finley BL, Tvermoes BE. 2014. Refined biokinetic model for humans exposed to cobalt dietary supplements and other sources of systemic cobalt exposure. Chem-Biol Interact 216:53–74; doi: 10.1016/j.cbi.2014.04.001. PMID: 24726710.

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting,San Antonio, TX, March 2013.

Kirman CR, Hays SM, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact 200(1):45-64; doi: 10.1016/j.cbi.2012.08.016.